Head-to-head · WeighScore
NativeMed vs NexLife
The verdict
NexLife takes it — 68.5/100 to 66.5/100, but only just.
NexLife grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NexLife is a LegitScript-certified telehealth platform offering compounded semaglutide (from $145/mo) and compounded tirzepatide (from $186/mo). NativeMed is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NativeMed | NexLife |
|---|---|---|
| WeighScore | 66.5/100 | 68.5/100 |
| Grade | C | C |
| Scorecard rank | #190 | #147 |
| Semaglutide | $149/mo (promotional rate, compounded) | $165/mo (compounded) |
| Tirzepatide | $183/mo (promotional rate, compounded) | $215/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #190 · C
Strengths
- LegitScript Certified (verifiable in the footer)
- Promotional pricing shown publicly: $149/mo semaglutide, $183/mo tirzepatide
- Online questionnaire intake, with a live visit added when state law requires it
Where it loses points
- Pharmacy partners aren't named — described only as 'USA-based' or 'accredited' pharmacies
- States served aren't listed publicly
- Prices are promotional — confirm whether they hold past month one or rise to the $299/$399 regular rate
Graded #147 · C
Strengths
- LegitScript certified platform
- Works exclusively with LegitScript-certified, NABP-accredited pharmacies — strongest pharmacy trust signal in the dataset
- Both semaglutide and tirzepatide at competitive pricing
- Semaglutide from $145/mo on the 12-month plan ($165/mo month-to-month) - among the lowest in the dataset
Where it loses points
- State availability not publicly disclosed
- Compounded only — no brand-name options
- Also covers hormone optimization and longevity
- Lowest advertised rates ($145 sema / $186 tirz) require a 12-month plan commitment
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.